Presentation is loading. Please wait.

Presentation is loading. Please wait.

Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor–Resistant Non–Small Cell Lung Cancer  Hiroaki Ogata,

Similar presentations


Presentation on theme: "Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor–Resistant Non–Small Cell Lung Cancer  Hiroaki Ogata,"— Presentation transcript:

1 Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor–Resistant Non–Small Cell Lung Cancer  Hiroaki Ogata, MD, Yuzo Yamamoto, MD, Taishi Harada, MD, PhD, Yoichi Nakanishi, MD, PhD, Isamu Okamoto, MD, PhD  Journal of Thoracic Oncology  Volume 12, Issue 5, Pages e46-e47 (May 2017) DOI: /j.jtho Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Histologic features of the patient’s bone marrow after termination of osimertinib treatment. Hematoxylin and eosin staining revealed marked hypocellularity. Journal of Thoracic Oncology  , e46-e47DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions


Download ppt "Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor–Resistant Non–Small Cell Lung Cancer  Hiroaki Ogata,"

Similar presentations


Ads by Google